Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more
Proteomics International Laboratories Ltd (PIQ) - Total Liabilities
Latest total liabilities as of June 2025: AU$1.81 Million AUD
Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has total liabilities worth AU$1.81 Million AUD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Proteomics International Laboratories Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Proteomics International Laboratories Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Proteomics International Laboratories Ltd Competitors by Total Liabilities
The table below lists competitors of Proteomics International Laboratories Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Halla Eng&Cons
KO:014790
|
Korea | ₩1.49 Trillion |
|
Chonbang
KO:000950
|
Korea | ₩9.17 Billion |
|
Tidehold Development Co Ltd
TW:9902
|
Taiwan | NT$94.39 Million |
|
GeneReach Biotechnology
TWO:4171
|
Taiwan | NT$285.79 Million |
|
Canagold Resources Ltd
OTCQB:CRCUF
|
USA | $3.38 Million |
|
Whitestone Group
BR:ROCK
|
Belgium | €410.99K |
|
Hanchem Co,. Ltd.
KQ:457370
|
Korea | ₩5.96 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Proteomics International Laboratories Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 6.54 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Proteomics International Laboratories Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual total liabilities of Proteomics International Laboratories Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.81 Million | +11.58% |
| 2024-06-30 | AU$1.63 Million | -7.20% |
| 2023-06-30 | AU$1.75 Million | -12.49% |
| 2022-06-30 | AU$2.00 Million | +102.21% |
| 2021-06-30 | AU$990.19K | -11.34% |
| 2020-06-30 | AU$1.12 Million | +75.99% |
| 2019-06-30 | AU$634.59K | -22.45% |
| 2018-06-30 | AU$818.30K | -36.04% |
| 2017-06-30 | AU$1.28 Million | +53.92% |
| 2016-06-30 | AU$831.17K | +14.33% |
| 2015-06-30 | AU$727.01K | +147.54% |
| 2014-06-30 | AU$293.69K | -- |